{"id":"W4306711477","doi":"10.1016/j.ejca.2022.10.003","title":"Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; Genentech; Aptitude Health; Oncolytics Biotech; Eisai; Seagen; Bayer HealthCare; G1 Therapeutics; Silverback Therapeutics; Puma Biotechnology; BioTheranostics; Ipsen; OncoSec Medical; Syndax Pharmaceuticals; Mersana Therapeutics; Queen Mary University of London; Clovis Oncology; Mylan; MacroGenics; Celldex Therapeutics; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Taiho Pharmaceutical; Ipsen Biopharmaceuticals; F. Hoffmann-La Roche; Radius Health; Amgen; Ariad Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; Baxalta; Foundation Medicine; Genomic Health; AbbVie; Revolution Medicines; Exelixis; Sanofi; Incyte; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Quality of life (healthcare); Breast cancer; Nausea; Population; Vinorelbine; Gemcitabine; Oncology; Eribulin; Metastatic breast cancer; Capecitabine; Cancer; Chemotherapy; Physical therapy; Colorectal cancer; Cisplatin","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003148596,0.0008885945,0.001664756,0.0002732508,0.0002424715,0.0007404033,0.0005455883,0.0007118277,0.002770473],"category_scores_gemma":[0.001729494,0.0002625363,0.001518701,0.0003993943,0.0008168318,0.0004318774,0.0003881051,0.00187011,0.0002876211],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000942947,"about_ca_system_score_gemma":0.00110826,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009141454,"about_ca_topic_score_gemma":0.002161628,"domain_scores_codex":[0.9989833,0.0007198189,0.00004255119,0.0000802972,0.00007655511,0.00009749942],"domain_scores_gemma":[0.9988074,0.000355891,0.0003394388,0.00007281121,0.00006611737,0.0003583842],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9756187,0.005076857,0.00338951,0.0002281903,0.000733107,0.00002803211,0.00005363024,0.0008369555,0.001686763,0.00004674279,0.0004936903,0.01180783],"study_design_scores_gemma":[0.6594201,0.3101287,0.02502076,0.00004680172,0.001110024,0.0001167146,0.0000425329,0.001770419,0.00102837,0.0001803243,0.001116077,0.00001910895],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968664,0.001465463,0.0001031797,0.0002069062,0.0000594468,0.0004340764,0.0003777874,0.00001228018,0.0004744657],"genre_scores_gemma":[0.996605,0.0007430649,0.0002943713,0.0002143019,0.0001145953,0.0006922683,0.0007948336,0.000005208749,0.000536241],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003148596,"threshold_uncertainty_score":0.01665157,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05695953814471598,"score_gpt":0.39383531743827,"score_spread":0.336875779293554,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}